Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine effect on glutamate/glutamine cycling in depression
NCT02037035Phase 1Completed
- Sponsor
- Yale University
- Start
- Jul 2013
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketamine in major depressive disorder (MDD) (2 arms), sponsored by Yale University. Primary endpoint: Glutamate/Glutamine Cycling. Started Jul 2013; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02037035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037035.